stockrowZoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024.
- Revenue
- −0.24%
- EPS
- +2.48%
- Free cash flow
- +17.4%
- Total debt
- +37.5%
Quarter to June 2026, against a year earlier
Follow ZTS
Alert me
Zoetis Inc. (ZTS) Return on equity
Zoetis Inc.'s return on equity over the twelve months to 30 June 2026 was 64.9%, down 1.1 percentage points from fiscal 2025 (66.0%). Over the past ten years it has ranged from 27.9% (fiscal 2015) to 71.9% (fiscal 2018); the current reading is higher than 91% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 66.0% | 15.05 |
| FY2024 | 50.9% | 1.04 |
| FY2023 | 49.9% | 2.64 |
| FY2022 | 47.3% | (1.72) |
| FY2021 | 49.0% | (1.57) |
| FY2020 | 50.6% | (10.76) |
| FY2019 | 61.3% | (10.61) |
| FY2018 | 71.9% | 19.32 |
| FY2017 | 52.6% | (10.80) |
| FY2016 | 63.4% | 35.48 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ZTS Zoetis Inc. | 64.9% |
| NBIX Neurocrine Biosciences, Inc. compare | 20.4% |
| UTHR United Therapeutics Corporation compare | 19.1% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 6.65% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| TAK Takeda Pharmaceutical Co. compare | 0.00% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| VTRS Viatris Inc. compare | −4.21% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement